Amplo Biotechnology

Executive Summary

Amplo Biotechnology is a preclinical-stage biotech company headquartered in San Diego, founded in 2020 with a mission to develop targeted adeno-associated virus (AAV) gene therapies for diseases affecting the neuromuscular junction (NMJ). The company's initial focus is on rare Congenital Myasthenic Syndromes (CMS), a group of genetic disorders that impair signal transmission at the NMJ, leading to muscle weakness and fatigue. By leveraging established AAV delivery and manufacturing platforms, Amplo aims to de-risk the development process for these niche patient populations. The company's strategy emphasizes efficiency and translational probability, targeting well-understood genetic targets with existing clinical precedent for AAV-based therapies. While still in preclinical development, Amplo Biotechnology has completed foundational research and is advancing toward regulatory filings. The company's pipeline remains undisclosed in detail, but it is positioned to address significant unmet needs in rare neuromuscular disorders. With no disclosed funding rounds or valuation, the company operates with a lean profile typical of early-stage biotechs. The upcoming milestones include potential IND-enabling studies and initial clinical trial applications. Amplo's focus on a specific therapeutic area with clear biological rationale may attract partnership interest from larger gene therapy players, particularly as manufacturing and delivery challenges for AAV continue to improve.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for CMS Lead Program40% success
• Q4 2026Initial Preclinical Data Publication70% success
• Q2 2027Series A Financing or Strategic Partnership50% success